There are 2137 resources available
905P - Outcomes of fludarabine, melphalan and low dose total body irradiation as a reduced intensity regimen in allogeneic peripheral blood stem cell transplantation
Presenter: Dipenkumar Modi
Session: E-Poster Display
Resources:
Abstract
906P - Infectious complications in patients with acute graft-versus-host disease
Presenter: Aleksandr Siniaev
Session: E-Poster Display
Resources:
Abstract
907P - Invasive aspergillosis caused by aspergillus non-fumigatus in children and adults after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: E-Poster Display
Resources:
Abstract
908P - Impact of serum galactomannan assay on diagnosis and outcome of invasive fungal infections in high risk febrile neutropenia: A prospective cohort study
Presenter: VIRAJ NEVREKAR
Session: E-Poster Display
Resources:
Abstract
1090P - Real-world (RW) clinical outcomes in patients (pts) with locally advanced (LA) or metastatic Merkel cell carcinoma (mMCC) treated in United States (US) oncology clinical practices: Results from SPEAR-Merkel
Presenter: Charles Cowey
Session: E-Poster Display
Resources:
Abstract
1092P - Non-progression with avelumab treatment in patients with metastatic Merkel cell carcinoma (mMCC) is associated with a clinically meaningful better health-related quality of life compared with progressive disease
Presenter: Murtuza Bharmal
Session: E-Poster Display
Resources:
Abstract
1592P - Happy wedding? Access and availability of oncology combination medicines
Presenter: Michele Pistollato
Session: E-Poster Display
Resources:
Abstract
1621MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Robin Jones
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1622MO - Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Presenter: John Zalcberg
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast